Biocon's Kiran Mazumdar-Shaw Gives A Reality Check On Ease Of Doing Business In India

Interview: Biocon's Chairman MD: Kiran Mazumdar-Shaw

Look forward to an IPO in next 18-24 months, says Biocon’s Kiran Mazumdar Shaw

Q2WithBQ With Biocon's Kiran Mazumdar Shaw

Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit

Corporate tax cut is a much needed reform, says Biocon's Kiran Mazumdar Shaw

Biocon’s Kiran Mazumdar Shaw On Who’ll Win The Battle Between ‘Innovators’ And Biosimilar Makers

kiran-mazumdar-shaw-at-global-technology-summit

Q4 Review: Biocon's Kiran Mazumdar Shaw On Earnings & FY23 Projections

Kiran Mazumdar Shaw On Fighting and Recovering From COVID-19: ‘Dont Panic, Be Positive

Kiran Mazumdar Shaw of Biocon on biosimilar & business outlook

Safe place to be in if coronavirus mortality rate brought down: Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw on why India needs to open up after May 3rd 

Kiran Mazumdar-Shaw | Compassionate capitalism

Kiran Mazumdar-Shaw | Entrepreneurship made me aware of social needs

Kiran Mazumdar-Shaw | Certain investments should be considered philanthropic

Kiran Mazumdar Shaw Backs Sikka & Team

Kiran Mazumdar Shaw: The entrepreneur ahead of her time

It's a very welcome move: Kiran Mazumdar-Shaw on WHO's nod for Covaxin

Kiran Mazumdar-Shaw | Advice to new philanthropists: where can you make a difference?

Kiran Mazumdar-Shaw | Philanthropy has to be sustainable

PNB's Growth Outlook For FY25 | NDTV Profit

Arvind SmartSpaces Q4 Revenue Rise 26.6% At ₹117.4 Cr | NDTV Profit

Key Growth Levers For Greaves Cotton And India Shelter | NDTV Profit

Tata Motors Q4 May Rise 25% to ₹6966 Cr | NDTV Profit

What Does FY25 Have In Store For CAMS? | NDTV Profit

VST Tillers Q4: Revenue Down 15% To ₹273 Cr | NDTV Profit

Biocon and HealthCare Global In Focus | Earnings Edge | NDTV Profit

Q1 Review: Biocon's Profit, Margins Fall; Misses Estimates

Q4 Review | Biocon March Quarter Net Profit Soars

Stocks In Focus: Biocon, CG Power and Industrials, LIC & More

Q2 Review: After Weak Q2, Can Biocon Bounce Back In Q3? | BQPrime

Biocon Withdraws Drug Application With EMA